Use of anticospecial plasma from healthy vaccinated people in the treatment of patients with severe coronavirus infection
- Authors: Tryshkin D.V1, Kryukov E.V2, Chernetcov V.A2, Chernov S.A2
-
Affiliations:
- The Main Military Medical Directorate of the Ministry of Defense of the Russian Federation
- The N.N.Burdenko Main Military Clinical Hospital of the Ministry of Defense of the Russia Federation
- Issue: Vol 342, No 2 (2021)
- Pages: 66-68
- Section: Articles
- URL: https://journals.eco-vector.com/0026-9050/article/view/82563
- DOI: https://doi.org/10.17816/RMMJ82563
- ID: 82563
Cite item
Open Access
Access granted
Abstract
The lack of effective etiotropic drugs against the new coronavirus infection has forced researchers around the world to look for other means of exposure to SARS-CoV-2. One such method is the introduction of immune plasma from those with a new coronavirus infection, COV1D-19. It is shown that the use of plasma reconvalescence in the early stages of the disease leads to a rapid regression of clinical symptoms of the disease, reduces the number of patients in need of artificial ventilation. But the high titer of antiviral antibodies is not all affected. With the advent of the domestic vaccine, it was possible to obtain immune plasma from vaccinated individuals. The article presents the world’s first experience of the introduction of anticospecies plasma, obtained from healthy people vaccinated with the domestic vaccine «Gam-COVID-Vac».
Full Text
About the authors
D. V Tryshkin
The Main Military Medical Directorate of the Ministry of Defense of the Russian FederationMoscow, Russia
E. V Kryukov
The N.N.Burdenko Main Military Clinical Hospital of the Ministry of Defense of the Russia FederationMoscow, Russia
V. A Chernetcov
The N.N.Burdenko Main Military Clinical Hospital of the Ministry of Defense of the Russia FederationMoscow, Russia
S. A Chernov
The N.N.Burdenko Main Military Clinical Hospital of the Ministry of Defense of the Russia Federation
Email: chernov.s.a@mail.ru
Moscow, Russia
References
- Аверьянов А.В., Перкина А.С., Сотникова А.Г. и др. Исследование безопасности плазмы реконвалесцентов в терапии COV1D-19 // Медиц. экстрем. сит. - 2020 (принята в печать).
- Баклаушев В.П., Аверьянов А.В., Сотникова А.Г. и др. Предварительные итоги исследования безопасности и эффективности плазмы реконвалесцентов в терапии COV1D-19 // Клин. практика. - 2020. - Т. 11, № 2. - С. 38-49.
- Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 9 (утв. Минздравом РФ 26.10.2020 г.). Доступно пo: https://base. garant.ru/74212510/ Ссылка активна на 12.06.2020 г.
- Клыпа Т.В., Бычинин M.B., Мандель И.А. и др. Клиническая характеристика пациентов с COV1D-19, поступающих в отделение интенсивной терапии, предикторы тяжелого течения // Клин. практика. - 2020. - Т. 11, № 2. - С. 6-20.
- Anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of COVID-19. https://ClinicalTrials.gov/ - 2020. NCT04292340.
- Cheng Y., Wong R., Soo Y. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong // Europ. J. Clin. Microbiol. Infect. Dis. - 2005. - Vol. 24, N 1. - P. 44-46.
- Convalescent plasma to limit coronavirus associated complications. https://ClinicalTrials.gov/ - 2020. NCT04325672.
- Dzik S. COVID-19 convalescent plasma: now is the time for better science // Transfus. Med. Rev. - 2020. - Vol. 34 (3). - P. 141-144.
- Duan K., Liu B., Li C. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients // Proc. Nat. Acad. Sci. USA. - 2020. - Vol. 117 (17). - P. 9490-9496.
- Hung I.F., To K.K., Lee C.K. et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection // Clin. Infect. Dis. - 2011. - Vol. 52, N 4. - P. 447-456.
- Hyperimmune plasma for critical patients with COVID-19 (COV 19-PLASMA). https://ClinicalTrials.gov/ - 2020. NCT04321421.
- Ко J.H., Seok H., Cho S. et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience // Antivir. Ther. (Lond). - 2018. - Vol. 23, N 7. - P. 617-622.
- Li L., Zhang W., Hu Y. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life - threatening COVID-19: a randomized clinical trial // JAMA. - 2020. - Vol. 324 (5). - P. 1-11.
- Safety in convalescent plasma transfusion to COVID-19. https://ClinicalTrials.gov/ - 2020. NCT04333355.
- Sean T.H. Liu, Hung-Mo Lin, Ian Baine et al. Convalescent plasma treatment of severe COVID-19: A matched control study // MedRxiv. - 2020. Available from https://www.medrxiv.оrg/content/l 0.1101/2020.05.20.20102236v
- Shen C., Wang Z., Zhao F. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma // JAMA. - 2020. - Vol. 323 (16). - P. 1582-1589.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).